Company: CERO
Filing Date: 2025-09-04
Form Type: 424B3
Source: 0001213900-25-084604
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-09-04
Form: 424B3
Chunk 3
---
 pending such hearing or any
extension provided by the Hearings Panel.

At such hearing, the
Company intends to submit a plan to regain compliance with the Stockholders’ Equity Requirement. Such plan of compliance may include
the increase in stockholders’ equity through the consummation of public or private financing transactions.

No assurances can be
provided that the Company will consummate any financing transactions, obtain a favorable decision from the Hearings Panel or that the
Company will be able to regain or maintain compliance with Nasdaq listing’s rules.

<div align='center'>1

SIGNATURE</div>

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| CERO THERAPEUTICS HOLDINGS, INC. |                         |
| By:                              | /s/ Chris Ehrlich       |
| Name:                            | Chris Ehrlich           |
| Title:                           | Chief Executive Officer |

Dated: September 4, 2025

<div align='center'>2</div>